@katem02134 You in #Melanoma? That's Checkmate 067 https://t.co/mc6wtpw3co by @bmsnews , series of regular updates in @NEJM such as https://t.co/oYrKaJDcAE
New post in Development of Pharmacy Channel: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/SfvajFI1Cb https://t.co/soUXjvp0PP
@JackWestMD I was convinced about the curative potential of IO after seeing the long-term curves in adv melanoma (https://t.co/WTZSyWEmGY) Similar curves in MSI-H tumors Then, there is the biological rationale, & the consistency: responses w/ IO tend
@Herzspitze @ainu_lai 52% 5-Jahresüberleben war eine Revolution! Das gab es früher einfach nicht. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM https://t.co/FGP80zPIVV
2/ #CheckpointInhibitors #Nivolumab - anti-PD-1 #Ipilimumab - anti-CTLA-4 They are used in combination for Rx of metastatic melanoma, and other cancers https://t.co/RLPP1fLczU
Promising results of immunotherapy in patients with advanced melanoma. Sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab, with no apparent loss of quality of life. https:
RT @jitcancer: Article #4 @gulleyj1 Feb #JITC reading list: Larkin, @wolchokj @PAscierto et al @NEJM w survival update from CM067 #melanoma…
RT @jitcancer: Article #4 @gulleyj1 Feb #JITC reading list: Larkin, @wolchokj @PAscierto et al @NEJM w survival update from CM067 #melanoma…
RT @jitcancer: Article #4 @gulleyj1 Feb #JITC reading list: Larkin, @wolchokj @PAscierto et al @NEJM w survival update from CM067 #melanoma…
RT @jitcancer: Article #4 @gulleyj1 Feb #JITC reading list: Larkin, @wolchokj @PAscierto et al @NEJM w survival update from CM067 #melanoma…
RT @gulleyj1: Incremental improvements in survival or not enough. The power of #Immunotherapy is that we may be able to cure a proportion o…
RT @gulleyj1: Incremental improvements in survival or not enough. The power of #Immunotherapy is that we may be able to cure a proportion o…
Incremental improvements in survival or not enough. The power of #Immunotherapy is that we may be able to cure a proportion of patients. This study talks about #melanoma, let’s do it another cancers too!
RT @jitcancer: Article #4 @gulleyj1 Feb #JITC reading list: Larkin, @wolchokj @PAscierto et al @NEJM w survival update from CM067 #melanoma…
がん医療の進歩凄い。 メラノーマは転移後5年生存率10%だったのが、オプジーボとヤーボイの併用で5年生存率52%。この5年でこんなに変わるのね。 https://t.co/gcz3uPo3Ge https://t.co/vpCV1HcqMi
RT @AndyBiotech: Just 10 yrs ago, only 1 in 20 patients with advanced #melanoma would survive for five yrs Now, more than half of pts surv…
RT @fgunico: Nivo/Ipi, resultados a los 5 años. Y con un IPT negativo .....🙄🙄 https://t.co/yw2E7ZMcWD https://t.co/LQMmrGjI2H
RT @fgunico: Nivo/Ipi, resultados a los 5 años. Y con un IPT negativo .....🙄🙄 https://t.co/yw2E7ZMcWD https://t.co/LQMmrGjI2H
RT @fgunico: Nivo/Ipi, resultados a los 5 años. Y con un IPT negativo .....🙄🙄 https://t.co/yw2E7ZMcWD https://t.co/LQMmrGjI2H
Nivo/Ipi, resultados a los 5 años. Y con un IPT negativo .....🙄🙄 https://t.co/yw2E7ZMcWD https://t.co/LQMmrGjI2H
RT @Zihai: The verdict is in. Any questions? #immunooncology https://t.co/Uxq4RgDkmS
RT @RevistaMFSamfyc: Supervivencia a los cinco años con nivolumab e ipilimumab combinados en el melanoma avanzado https://t.co/7bCi5J5fGp P…
Supervivencia a los cinco años con nivolumab e ipilimumab combinados en el melanoma avanzado https://t.co/7bCi5J5fGp PMID 31562797
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM https://t.co/imMRLyqHI2
5-year survival in Metastatic Melanoma... https://t.co/LBlmPQ8fzM
進行性メラノーマの免疫チェックポイントの5年生存率。ニボにイピリマブあってもなくても変わらない。 Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. - PubMed - NCBI https://t.co/tdnpk3J03d
RT @SeeFisch: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM https://t.co/GYzohoOWCe
RT @Kenrickng1: Have been approached by a few colleagues discussing results of #checkmate067. 1. Does this justify the addition of #ipilimu…
Have been approached by a few colleagues discussing results of #checkmate067. 1. Does this justify the addition of #ipilimumab to #nivolumab in the context of the increased toxicity profile in ##melanoma ? 2. Have we reached the survival plateau for both K
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
RT @LeylaEDelpouve: Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda…
Son derece agresif olan ileri evre Melanoma’da yeni sonuçlar var. ipilumumab (Yervoy)+Nivolumab(Opdivo) kombinasyonunda %22 olan 5 yıllık sağ kalım oranı %60 olmuş Veriler şaşırtıcı ve güzel.Melanoma ile baş ediliyor, umarım sağ kalım daha da artacak http
RT @lemelbaum: New data for ipilimumab-Nivolumab combination have been published. The data are staggering. 60% of patients are alive at 5 y…
RT @lemelbaum: New data for ipilimumab-Nivolumab combination have been published. The data are staggering. 60% of patients are alive at 5 y…
RT @lemelbaum: New data for ipilimumab-Nivolumab combination have been published. The data are staggering. 60% of patients are alive at 5 y…
RT @lemelbaum: New data for ipilimumab-Nivolumab combination have been published. The data are staggering. 60% of patients are alive at 5 y…
RT @lemelbaum: New data for ipilimumab-Nivolumab combination have been published. The data are staggering. 60% of patients are alive at 5 y…
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @AndyBiotech: Just 10 yrs ago, only 1 in 20 patients with advanced #melanoma would survive for five yrs Now, more than half of pts surv…
RT @NEJM: With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of n…
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of n…
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @drbenekli: Nivo + ipi ile >24 ay sağkalım farkı müthiş bir rakam (median OS: Nivo + ipi > 60 ay, nivo 36 ay, ipi 20 ay). Biz hala önce…
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @itoprag: Great results. OS 60 months (and going) with nivo+ipi vs 36.9m with nivo/19.9m with ipi alone. Five-Year Survival with Combin…
RT @drbenekli: Nivo + ipi ile >24 ay sağkalım farkı müthiş bir rakam (median OS: Nivo + ipi > 60 ay, nivo 36 ay, ipi 20 ay). Biz hala önce…
#NEJM La survie à cinq ans est plus importante sous traitement combiné [Nivolumab+Ipilimumab] (...) que sous traitement Ipilimumab seul; chez les patients atteints d’un mélanome avancé.
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @drbenekli: Nivo + ipi ile >24 ay sağkalım farkı müthiş bir rakam (median OS: Nivo + ipi > 60 ay, nivo 36 ay, ipi 20 ay). Biz hala önce…
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @dr_gilgson: Absolutely stunning, we do need such a gamechanger in HPB cancers @hpb_so https://t.co/FysGJw9qYh
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @dr_gilgson: Absolutely stunning, we do need such a gamechanger in HPB cancers @hpb_so https://t.co/FysGJw9qYh
RT @drbenekli: Nivo + ipi ile >24 ay sağkalım farkı müthiş bir rakam (median OS: Nivo + ipi > 60 ay, nivo 36 ay, ipi 20 ay). Biz hala önce…
RT @drbenekli: Nivo + ipi ile >24 ay sağkalım farkı müthiş bir rakam (median OS: Nivo + ipi > 60 ay, nivo 36 ay, ipi 20 ay). Biz hala önce…
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
Indeed quite a toxic regimen and thus only suitable for selected patients, the combined checkpoint blockade with ipilimumab and nivolumab shows impressive long-term results in patients with malignant #melanoma
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
Absolutely stunning, we do need such a gamechanger in HPB cancers @hpb_so
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
New data for ipilimumab-Nivolumab combination have been published. The data are staggering. 60% of patients are alive at 5 years. 75% of patients do not require further therapy. This is truly a revolution but we always aim at 100% at 5 years. https://t.c
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
RT @NEJM: Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
Original Article: Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/2Nr6bWbZo5
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM https://t.co/JpQUT8gjti
A new study is out in the New England Journal of Medicine called "Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma." You can request this article through your library resources. https://t.co/4fS2vzN9ux
RT @dhjutsw1: Truly stunning results. @UTSWIMchief @UTSWInternalMed @guptaarjun90 @DinoKazi https://t.co/DwECCi5Ocz https://t.co/LZ…
RT @dhjutsw1: Truly stunning results. @UTSWIMchief @UTSWInternalMed @guptaarjun90 @DinoKazi https://t.co/DwECCi5Ocz https://t.co/LZ…
RT @NEJM: With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of n…
50% overall survival at 5 years in pts with locally advanced and metastatic melanoma treated with Nivolumab and Ipilimumab Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM https://t.co/QyoUMlEpT7
RT @dhjutsw1: Truly stunning results. @UTSWIMchief @UTSWInternalMed @guptaarjun90 @DinoKazi https://t.co/DwECCi5Ocz https://t.co/LZ…
RT @dhjutsw1: Truly stunning results. @UTSWIMchief @UTSWInternalMed @guptaarjun90 @DinoKazi https://t.co/DwECCi5Ocz https://t.co/LZ…
Combination immunotherapy in melanoma, important tool to #fightcancer
Truly stunning results. @UTSWIMchief @UTSWInternalMed @guptaarjun90 @DinoKazi https://t.co/DwECCi5Ocz https://t.co/LZKwKHJjnJ
RT @Aiims1742: Perfectly timed with @wolchokj @NEJM paper this week 👇🏾 https://t.co/5ime8Vi4DZ Cc: @DrMiguelPerales @sloan_kettering @parke…